AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-23.2%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.01B
AUM Growth
+$2.01B
(-30%)
Cap. Flow
+$140M
Cap. Flow
% of AUM
6.96%
Top 10 Holdings %
Top 10 Hldgs %
70.26%
Holding
110
New
9
Increased
21
Reduced
12
Closed
14
Top Buys
| 1 |
Moderna
MRNA
|
$80.3M |
| 2 |
Alibaba
BABA
|
$47.6M |
| 3 |
NIO
NIO
|
$26.1M |
| 4 |
Allogene Therapeutics
ALLO
|
$10.8M |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
$8.55M |
Top Sells
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$31.2M |
| 2 |
Amicus Therapeutics
FOLD
|
$9.58M |
| 3 |
AnaptysBio
ANAB
|
$9.57M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
$7.29M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$7.29M |
Sector Composition
| 1 | Healthcare | 65.65% |
| 2 | Consumer Discretionary | 33.07% |
| 3 | Real Estate | 0.37% |
| 4 | Communication Services | 0.16% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
WW
1
DELISTED
WW International
WW
| $571M | 21.16% | 14,818,300 | – | – |
|
2
Lexicon Pharmaceuticals
LXRX
$400M
| $400M | 14.82% | 60,240,864 | – | – |
|
|
ONC
3
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $84.2M | 3.12% | 600,000 | – | – |
|
|
4
Moderna
MRNA
$9.37B
| $80.3M | 2.97% | +5,256,298 | New | +$80.3M |
|
|
5
Alibaba
BABA
$322B
| $56.5M | 2.09% | 412,000 +347,000 | +534% | +$47.6M |
|
6
Scholar Rock
SRRK
$3.14B
| $52.7M | 1.95% | 2,296,040 -100,000 | -4% | -$2.3M |
|
|
RUBY
7
DELISTED
Rubius Therapeutics, Inc
RUBY
| $46.8M | 1.73% | 2,908,791 | – | – |
|
|
XLRN
8
DELISTED
Acceleron Pharma Inc.
XLRN
| $45.7M | 1.69% | 1,050,000 +50,000 | +5% | +$2.18M |
|
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $36.5M | 1.35% | 500,000 -100,000 | -17% | -$7.29M |
|
|
10
NIO
NIO
$14.3B
| $35.7M | 1.32% | 5,600,000 +4,100,000 | +273% | +$26.1M |
|
|
ARRY
11
DELISTED
Array Biopharma Inc
ARRY
| $35.6M | 1.32% | 2,500,000 +600,000 | +32% | +$8.55M |
|
12
Atara Biotherapeutics
ATRA
$84.6M
| $34.7M | 1.29% | 1,000,000 | – | – |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $32.3M | 1.2% | 600,000 +100,000 | +20% | +$5.39M |
|
|
14
Amicus Therapeutics
FOLD
$2.34B
| $28.7M | 1.06% | 3,000,000 -1,000,000 | -25% | -$9.58M |
|
15
Fate Therapeutics
FATE
$120M
| $27.6M | 1.02% | 2,150,000 -40,000 | -2% | -$513K |
|
16
Nektar Therapeutics
NKTR
$568M
| $26.3M | 0.97% | 800,000 | – | – |
|
17
argenx
ARGX
$43.6B
| $25.9M | 0.96% | 270,000 +85,000 | +46% | +$8.17M |
|
18
ProQR Therapeutics
PRQR
$237M
| $22.1M | 0.82% | 1,400,000 +100,000 | +8% | +$1.58M |
|
19
Agios Pharmaceuticals
AGIO
$2.19B
| $18.4M | 0.68% | 400,000 +100,000 | +33% | +$4.61M |
|
20
InflaRx
IFRX
$108M
| $18.2M | 0.67% | 500,000 | – | – |
|
21
Xencor
XNCR
$580M
| $18.1M | 0.67% | 500,000 | – | – |
|
|
BLUE
22
DELISTED
bluebird bio
BLUE
| $17.4M | 0.64% | 175,000 | – | – |
|
|
AUTL
23
Autolus Therapeutics
AUTL
$399M
| $15.6M | 0.58% | 475,000 -25,000 | -5% | -$821K |
|
24
FibroGen
FGEN
$47.8M
| $13.9M | 0.51% | 300,000 +50,000 | +20% | +$2.31M |
|
25
Solid Biosciences
SLDB
$427M
| $13.4M | 0.5% | 500,000 +275,000 | +122% | +$7.37M |
|